表紙
市場調査レポート

オートパッチクランプ市場の動向:2015年

Automated Patch Clamping Trends 2015

発行 HTStec Ltd 商品コード 300203
出版日 ページ情報 英文 53 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
オートパッチクランプ市場の動向:2015年 Automated Patch Clamping Trends 2015
出版日: 2015年10月02日 ページ情報: 英文 53 Pages
概要

当レポートでは、オートパッチクランプ (APC) 技術を用いたイオンチャネルドラッグスクリーニングのベンチマーキング調査の結果から、APCの現在の利用状況と今後の利用・購入計画、予算、選定基準、各種好みと要件・要望などについてまとめています。

  • エグゼクティブサマリー
  • 調査手法
  • 回答者のプロファイル
  • 回答者が行っているイオンチャネル研究活動
  • 回答者がもっとも興味を持っているイオンチャネルクラス
  • 研究中のイオンチャネルドラッグディスカバリープログラムの数
  • APCプラットフォームを用いて処理されるAPCウェルの数
  • APCアッセイで用いられる各種セルタイプの割合
  • 回答者が現在アクセスできるAPCプラットフォーム
  • APCシステムの好みのベンダー:各種基準別
  • APCシステムで重視する機能
  • 調査結果のサマリー (1)
  • 今後数年で新たにAPCプラットフォームを購入する予定・見通し
  • 購入する可能性のある新規APCプラットフォームの数
  • 将来の購入においてもっとも有望なAPCプラットフォーム
  • APCプラットフォームの購入にあたりもっとも重要な要素
  • APC用消耗品予算
  • APC用消耗品市場の推計
  • 新規APCプラットフォーム市場の推計
  • APC用消耗品の利用を妨げている要因
  • マルチホールパッチチップの好み
  • 新たな384 APCプラットフォームのスクリーニングへの影響
  • 新たな384ウェルAPCスクリーニングプラットフォームのAPC用消耗品の価格帯
  • 384ウェルAPCシステムの最重要機能
  • 完全な実験に求められるAPCの成功率
  • APCのHTSシステムへのシステム統合における好みのパートナー
  • 統合型APC HTSシステムの完全な自動化に必要なステップ
  • ベンチトップAPCプラットフォームに求められるソフトウェアの柔軟性
  • 完全自動化APCプラットフォームでの処理プレート数
  • 調査結果のサマリー (2)
  • 1536ウェルフォーマットにおけるAPCシステムの購入への関心
  • APC解析でもっとも活用されているスクリーニングソリューション
  • APCデータ解析に用いられるスクリーニングソリューションの統合のニーズ
  • APCデータの解析法
  • 測定済みAPCデータの再解析の頻度
  • FDAのCIPA Cardiac Risk Panelの認識
  • CIPA要件を満たした場合に導入が期待される技術
  • トランスポーターメカニズムの調査に採用される技術
  • Surfe2r技術の導入への意識・関心
  • 蛍光ベースのアッセイが依然としてAPCの代替となっている領域
  • 今後の蛍光ベースのアッセイの継続利用を推進する主な要因
  • 蛍光ベースのアッセイがAPCアッセイの許容できる代替となっている領域
  • 調査結果のサマリー (3)

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Executive Summary

This market report summarizes the results of HTStec's industry-wide global web-based benchmarking survey on ion channel drug screening using automated patch clamping (APC) technology carried out in September 2015.

The study was initiated by HTStec as part of its ongoing tracking of life science marketplaces and to update HTStec's previous report on the subject (published April 2014).

The questionnaire was compiled to meet the needs and interests of ephys/APC vendor community.

The objective of this global benchmarking study was to comprehensively document current practices, preferences and metrics in ion channel drug screening using APC technology. The questionnaire also addressed the use of 384-well APC systems, HTS integration and data analysis of APC systems, safety and transporter assays, and fluorescence as an alternative technique to APC.

Equal emphasis was given to soliciting opinion from Pharma, Other Screening Labs, Academic Research and Contract Research Organisation segments in North America, Europe and Japan.

The survey looked at the following aspects of ion channel screening using APC technology, as practiced today (2015) and in some cases as predicted for the future (2017): ion channels classes of greatest interest; number of ion channel programs investigated; number of APC patch wells expected to be processed per year; proportion of APC assays using different cell types; current access to APC ion channel platforms; preferred vendor's APC systems for different criteria; importance of features found in some APC systems; likelihood of purchasing a new APC platform over the next few years; factors that most influence a decision to purchase a particular APC platform; APC consumables budget for ion channel screening; what factors most prevent making greater use APC consumables today; preferences for multi-hole patch chips; whether the recent introduction of new 384-well APC screening platforms will affect screening activities; prohibitive and stimulative APC consumable pricepoints; most important features in a 384-well plate APC system; success rates required for completed experiments; preferred partners for system integration of an APC system into an automated HTS environment; steps which must be fully automated in an APC HTS system; flexibility required to modify or adapt vendor-recommended product protocols; number of plates to be processed in a fully automated APC HTS system; interest in purchasing a 1536-well APC system; screening solution utilized for APC data analysis and the integration needs of the preferred screening solution; how APC data is analysed and the frequency of reanalyzing measured APC data; awareness of the FDA CIPA working group and its potential impact on safety assays undertaken; techniques expected to be applied when fulfilling CIPA requirements; techniques used to investigate transporter assays; interest in Surfe2r technology for transporters; where fluorescence-based assays are still used as an alternative to APC for ion channel screening; main drivers for continuing to deploy fluorescence-based assays; and for which ion channel targets are fluorescence-based assays an acceptable alternative to APC assays.

The survey questionnaire consisted of 32 mainly multi-choice questions. In addition, there were 6 questions related solely to survey demographics.

The survey collected 138 validated responses, of these 62% provided comprehensive input.

Survey responses were geographically split: 44% Europe; 33% North America; 10% Japan; 5% India; 4% Rest of World; and 4% China.

Survey respondents were drawn from persons or groups actively involved in ion channel screening, selectivity profiling and safety assessment against ion channel liabilities using APC systems.

Respondents represented: 61 University/Res.Inst./Gov't Lab/Not-For-Profit; 26 Contract Research Organisation; 21 Large Pharma; 14 Medium-Small Pharma; 10 Biotech Company; 3 Agrochemical/Agri-Biotech Company; 2 Biopharma; and1 Academic Screening Center.

Most survey respondents had a senior job role or position which was in descending order: 46 senior scientists/researchers; 15 post-docs; 15 section/group leaders; 14 principal investigators; 10 professors/ assistant professors; 10 directors; 9 research scientists/associates; 8 lab managers; 5 others; 3 department heads; and 3 vice presidents.

Survey results were expressed as an average of all survey respondents. In addition, where appropriate the data was reanalyzed after segmentation into the following 6 survey groups: 1) Pharma; 2) Other Screening Labs; 3) Academic Research; 4) CROs; 5) Europe; and 6) North America.

The ion channel research activity undertaken by most respondents was assay development.

The class of ion channels of most interest was voltage-gated sodium channels.

A median of 3 ion channel programs were under investigation in respondent's organisations.

A median 1K-5K wells were processed per year using APC in all drug discovery areas.

The cell type most used for APC assays today was recombinant cell lines.

The most common APC system available for use in respondent's labs was the Sophion QPatch 8, 16 or HT.

Based on the prevalence of available APC instruments Nanion had the greatest vendor share.

From a list of desired characteristics/attributes Nanion was the most preferred APC vendor.

Suitability for different cell types was rated as the most important feature found in APC systems.

The likelihood of purchasing a new APC platform by end of 2017 was medium (10-50% probability).

The APC platforms respondents currently find most appealing for purchasing were Nanion Syncropatch 384/768PE and Sophion Qube.

The quality of the results was the factor which would most influence a decision to purchase a particular brand/model of APC platform.

The median annual APC consumable budget was $10K-$25K/year today.

Several bottom-up models were developed around the respondent's feedback to calculate the global APC markets. In 2015 these were estimated to be around $115M for APC consumables and $36M for new 384-well APC platforms. Segmentation & some CAGR estimates are in the full report.

The factor that most prevents greater use of APC consumables today was lack of projects.

The preferred patch chips were those with a single hole or pore per well.

The availability of patch chips with holes of different aperture sizes was identified as important.

The most predicted effect of the introduction of new 384-well APC screening platforms was to initiate APC screening at an earlier point in the drug discovery process.

For new 384-well APC screening platforms the median prohibitive price point (i.e. limits use to certain applications & inhibits adoption) was $1.00 per APC data point and $250-$300 per 384 patch plate.

The possibility to perform repetitive ligand applications (in well normalization) was the feature most want to access in a 384-well APC system.

Most respondents prefer to operate an APC instrument standalone (i.e. not integrated).

The preferred system integration partner for APC into an HTS environment was Beckman Coulter.

APC measurement was rated the step most want to fully automate when integrating an APC system.

Moderate software flexibility (i.e. example methods provided with option to change method and parameters) was most wanted in a benchtop APC platform.

The median number of plates to be processed without user intervention or per 8h day in a fully automated APC platform was 5 to 10 plates.

The majority had no interest in purchasing APC systems in 1536-well format.

The majority utilized an in house/customer-build solution in their organization for APC data analysis.

In terms of the integration needs with respect to the screening solution used for APC data analysis most respondents wanted full raw data current/voltage traces.

The majority reported additional manual steps (e.g. formatting) are required before analysing APC data.

The majority occasionally revisit measured APC data and perform reanalysis with a different set of parameters (cursors).

The majority were aware of the FDA CIPA working group where the cardiac risk panel was questioned and predict an increase in their future safety assay budget as a result of CIPA requirements.

The majority expect APC on stem cells/cell lines to feature highly when fulfilling CIPA requirements.

The majority reported they are not investigating transporter assays. Of those respondents investigating transporter measurements the most used technique was fluorescence uptake assays.

The majority were aware of the direct transport assay for electrogenic transporters using Surfe2r technology from Nanion and expressed possible interest in deploying this technology.

The area where fluorescence-based assays are still most routinely used as an alternative to APC for ion channel testing was primary screening (HTS), with throughput needs ranked the major driving force to continue to deploy fluorescence-based assays today.

Slow voltage-gated channels are the targets where fluorescence-based assays are regarded as the most acceptable alternative to APC assays.

The full report provides the data, details of the breakdown of the responses for each question, its segmentation and the estimates for the future (2017). It also highlights some interesting differences between the survey groups.

Table of Contents

  • Executive Summary
  • Survey Methodology
  • Respondent's Organisation & Response To The Survey
  • Respondent's Company Or Organisational Origin
  • Respondent's Geographic Origin
  • Respondent's Job Role
  • Ion Channel Research Activities Undertaken By Respondents
  • Classes of Ion Channels of Most Interest to Respondents
  • Number Of Ion Channel Drug Discovery Programs Under Investigation (1)
  • Number Of Ion Channel Drug Discovery Programs Under Investigation (2)
  • Number Of APC Well Processed Per Year Using An APC Platform
  • Proportion Of Different Cell Types Used In APC Assays
  • APC Platforms Respondents Currently Have Access To
  • Preferred Vendor's APC System For Various Criteria
  • Value Placed On Features Found In APC Systems
  • Summary Of Survey Findings (1)
  • Likelihood Will Purchase A New APC Platform Over The Next Few Years
  • Number Of Units Of A New APC Platform Respondents Might Purchase
  • APC Platforms Most Appealing For Future Purchasing
  • Factors Which Would Most Influence Purchasing Of APC Platform
  • APC Consumables Budget
  • APC Consumables Market Estimate
  • New APC Platforms Market Estimate
  • Factors Preventing Greater Use Of APC Consumables
  • Preference For Multihole Patch Chips
  • How New 384 APC Platforms May Affect Screening Activities
  • APC Consumable Pricepoints For New 384-Well APC Screening Platforms
  • Most Important Features In A 384-Well APC System
  • APC Success Rate Required For Completed Experiments
  • Preferred Partner For System Integration Of APC Into An HTS System
  • Steps That Must Be Fully Automated In An Integrated APC HTS System
  • Software Flexibility Required In A Benchtop APC Platform
  • Number Of Plates To Be Processed In A Fully Automated APC Platform
  • Summary Of Survey Findings (2)
  • Interest In Purchasing APC Systems In 1536 Well Format
  • Screening Solution Most Utilized For APC Analysis
  • Integration Needs A Screening Solution Used For APC Data Analysis
  • How APC Data Is Analyzed
  • Frequency Of Reanalyzing Measured APC Data
  • Awareness Of FDA CIPA Cardiac Risk Panel
  • Techniques Expected To Be Applied When Fulfilling CIPA Requirements
  • Techniques Employed To Investigate Transporter Mechanisms
  • Awareness & Interest In Deploying Surfe2r Technology
  • Areas Where Fluorescence-Based Assays Are Still An Alternative To APC
  • Major Driving Force To Continue To Deploy Fluorescence-Based Assays
  • Targets Where Fluorescence-Based Assays Are An Acceptable Alternative To APC Assays
  • Summary Of Survey Findings (3)
Back to Top